L P Papaian

  • Citations Per Year
Learn More
AIM To study the incidence of mutation of Leyden's factor V in patients with venous thrombosis and the hemostatic system in carrier of this genetic defect. MATERIALS AND METHODS A hundred and one patients aged 15-69 years who had venous thrombosis and 10 individuals with mutation of Leyden's factor V without manifestations in the history of thrombosis(More)
A method for measuring Willebrand's factor protein has been developed, based on indirect solid-phase enzyme immunoassay with Soviet monoclonal antibodies to this factor. Normal Willebrand's factor level in the plasma has been found 55-161 percent. The method has been tried in patients with Willebrand's disease and with oncologic diseases.
Abnormalities of platelet and plasma Willebrand's factor produce noticeable effects on the clinico-laboratory manifestations of Willebrand's disease. This is confirmed by more pronounced gravity of the hemorrhagic syndrome, the lack of the correcting effect in response to physiological conditions (pregnancy) and administration of DDAVP in contrast to(More)
A method for Willebrandt factor antigen measurement in platelets has been developed based on indirect solid-phase enzyme immunoassay with monoclonal antibodies. The mean platelets Willebrandt factor level in 17 normal subjects was 21.5% (S = +/- 8.88; S mean = 2.16%). The method was tried in a group of patients with Willebrandt's disease. A relationship was(More)
A single-stage method is used for evaluating factor VIII (fVIII) clotting activity. This method is based on evaluation of activated partial thromboplastin time with fVIII-deficient plasma as the substrate. The activity of fVIII in the plasma is estimated by the graphic analytical method, which is difficult and not sufficiently accurate. An analytical method(More)